Pregled bibliografske jedinice broj: 329486
How to differentiate frontotemporal from Alzheimer's dementia? Recent developments in molecular genetics and neuropathology
How to differentiate frontotemporal from Alzheimer's dementia? Recent developments in molecular genetics and neuropathology // Zdravniški vestnik, 77 (2008), 2; 71-74 (podatak o recenziji nije dostupan, članak, znanstveni)
CROSBI ID: 329486 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
How to differentiate frontotemporal from Alzheimer's dementia? Recent developments in molecular genetics and neuropathology
Autori
Liščić, Rajka
Izvornik
Zdravniški vestnik (1318-0347) 77
(2008), 2;
71-74
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Alzheimer's disease; frontotemporal lobar degeneration; clinical and psychometric distincion; TDP-43; PGRN mutation
Sažetak
Frontotemporal dementia is a major cause of non-Alzheimer dementia (AD). Frontotemporal lobar degeneration (FTLD) is used here as an umbrella term for both clinical and neuropathological entities starting before age of 65 years. FTLD differs clinically from AD because memory loss is rarely an early symptom. Instead, the dementia of FTLD is usually denoted by behavioral and language difficulties, although clinical and cognitive features of FTLD may overlap with AD. Aphasia may be prominent, either fluent or nonfluent. Clinical FTLD is associated with a variety of different neuropathological entities, which share common feature of preferential degeneration of the frontal and temporal lobes. Whereas, in the past, most attention focused on FTLD pathology associated with tau-positive inclusions and microtubule associated protein tau gene (MAPT) mutations (tauopathies), there has recently been greater attention paid to non-tau, ubiquitin positive inclusions (FTLD-U) or non-tauopathies. It is now recognized that FTLD-U is the most common pathology associated with clinical FTLD. Clinically, cases with FTLD-U may additionally present with or without motor neuron disease and parkinsonism. Majority of familial cases of FTLD-U have mutations in the progranulin (PRGN) gene. Some families of FTLD-U with PGRN mutation (hereditary dysphasic disinhibition dementia 1 and 2) are characterized, besides behavior and language difficulties, by additional memory loss and AD-type pathology. Recently, the ubiquitinated pathological protein in FTLD-U has been identified as TAR DNA binding protein (TDP 43) and found in an increasing number of neurodegenerative diseases, including AD. The overlap between FTLD-U and AD is important since as many as 20% of AD cases show some FTLD-U type TDP-43 pathology. Recent developments have helped to clarify the relationship between different types of FTLD and related conditions. Understanding and differentiating between FTLD and AD is very important for the diagnosis when new diagnostic test and therapeutics are becoming realized.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
Napomena
Special Issue on Neuroscience
POVEZANOST RADA
Projekti:
022-1340036-2083 - Frontotemporalne demencije (Liščić, Rajka, MZOS ) ( CroRIS)
098-0982522-2457 - Farmakogenomika i proteomika serotoninskog i kateholaminskog sustava (Muck-Šeler, Dorotea, MZOS ) ( CroRIS)
Ustanove:
Institut za medicinska istraživanja i medicinu rada, Zagreb,
Institut "Ruđer Bošković", Zagreb
Profili:
Rajka Liščić
(autor)
Citiraj ovu publikaciju:
Uključenost u ostale bibliografske baze podataka::
- BIOSIS Previews (Biological Abstracts)